Finoriq research workspace
Aura Biosciences, Inc. (AURA) Historical Metrics
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat. Review AURA valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
- Company
- Aura Biosciences, Inc. (AURA)
- Ticker
- AURA
- Market Cap
- $704.4M
- Latest Price
- $6.81
- Industry
- Biotech & Pharma
Aura Biosciences, Inc. (AURA) Current Valuation Metrics
Static valuation preview for Aura Biosciences, Inc. (AURA). Market data retrieved 2026-07-09. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| Earnings YieldLatest TTM net income divided by market cap. | -15.5% | Net Income | TTM Q1 2026 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | -12.6% | Operating Cash Flow | TTM Q1 2026 |
| Price / BookMarket cap divided by stockholders' equity. | 6.75x | Stockholders' Equity | Q1 2026 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.